Feature | Published:

Old dogma, new tricks—21st Century phage therapy

Nature Biotechnology volume 22, pages 3136 (2004) | Download Citation

Subjects

As antibiotic resistant bacteria threaten a public health crisis, biotechnology is turning to bacteriophages, nature's tiniest viruses. But can phage therapy overcome its historical baggage?

  • Subscribe to Nature Biotechnology for full access:

    $250

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    US Centers for Disease Control, the Food and Drug Administration and the US National Institutes of Health. A Public Health Action Plan to Combat Antimicrobial Resistance (CDC, FDA & NIH, June, 2000) ().

  2. 2.

    et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207–208 (2001).

  3. 3.

    , et al. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrobial Agents Chemother. 42, 1088–1092 (1998).

  4. 4.

    Concerns raised over declining antiinfective R&D. Nat. Biotechnol. 21, 1255–1256 (2003).

  5. 5.

    et al. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J. Virol. 75, 2509–2515 (2001).

Download references

Author information

Affiliations

  1. Karl Thiel is a freelance writer based in Portland, Oregon, USA.

    • Karl Thiel

Authors

  1. Search for Karl Thiel in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt0104-31

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.